Novartis has been among the largest so far in 2025, with plans to cut 427 jobs at its East Hanover site. The pharmaceutical ...

After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with a ...

Meanwhile, fellow Swiss company Novartis will no longer use diverse panels in its hiring process for U.S.-based employees, ...

Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a ...

Roche Holding AG scrapped long-held global diversity targets for its leadership, showing how pressure from the Trump ...

The National Football League (NFL) announced Novartis as its first-ever corporate pharmaceutical partner on March 13.

Swiss pharmaceutical giants Roche and Novartis are revising their diversity policies in response to recent U.S. executive ...

In the time since the Novartis gene therapy Zolgensma was approved for babies with spinal muscular atrophy, other treatments ...

A pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the ...

Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...

Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG (NOVN – Research Report) on March 17 and set a price target of ...

Novartis Pharmaceuticals is removing hundreds of New Jersey employees from its company. The global drugmaker will lay off 427 ...